Trial Profile

A phase II clinical trial of utidelone injectable in combination with etoposide and bevacizumab for HER2 negative BCBM patients

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Depoxythilone (Primary) ; Bevacizumab; Etoposide
Indications Brain metastases; HER2 negative breast cancer
Focus Therapeutic Use

Most Recent Events

08 Apr 2024 New trial record
29 Mar 2024 Results (N=17), assessing excellent central nervous system (CNS) overall response rate (ORR) and CNS clinical benefit rate, presented in a Biostar media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com